← All postsCategory

Regulatory

3 posts in this category, sorted most recent first.

2 May 2026·8 min read
After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
united-states compounded-glp1 fda regulatory
23 Apr 2026·4 min read
Research use only: the legal shield, not the barrier
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
research-use-only regulatory peptide-basics
23 Apr 2026·5 min read
US peptide regulation in 2026: the HHS reclass and what it means
RFK and HHS moved most restricted peptides back to Category 1 in early 2026. Here is what that actually does, and what it does not.
regulatory us fda hhs

Other categories

Buyer's guide 19 Evidence 15 Compound guide 7 Operations 6 Science 4 Thailand Medical Tourism 4 Protocols 2 Comparisons 1 Longevity 1 Pricing 1 Safety 1 Thailand Th 1 Us Market 1 Vendor Trust 1